Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/105324 https://doi.org/10.3390/ph14010060 |
Resumo: | Cancer, one of the most mortal diseases worldwide, is characterized by the gain of specific features and cellular heterogeneity. Clonal evolution is an established theory to explain heterogeneity, but the discovery of cancer stem cells expanded the concept to include the hierarchical growth and plasticity of cancer cells. The activation of epithelial-to-mesenchymal transition and its molecular players are widely correlated with the presence of cancer stem cells in tumors. Moreover, the acquisition of certain oncological features may be partially attributed to alterations in the levels, location or function of nucleolin, a multifunctional protein involved in several cellular processes. This review aims at integrating the established hallmarks of cancer with the plasticity of cancer cells as an emerging hallmark; responsible for tumor heterogeneity; therapy resistance and relapse. The discussion will contextualize the involvement of nucleolin in the establishment of cancer hallmarks and its application as a marker protein for targeted anticancer therapies. |
id |
RCAP_e6a39dede968fc15a070b0c2e2596d6c |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/105324 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesistumor heterogeneitydrug resistancecancer stem cellsnucleolintargeted therapiesepithelial-to-mesenchymal transitionCancer, one of the most mortal diseases worldwide, is characterized by the gain of specific features and cellular heterogeneity. Clonal evolution is an established theory to explain heterogeneity, but the discovery of cancer stem cells expanded the concept to include the hierarchical growth and plasticity of cancer cells. The activation of epithelial-to-mesenchymal transition and its molecular players are widely correlated with the presence of cancer stem cells in tumors. Moreover, the acquisition of certain oncological features may be partially attributed to alterations in the levels, location or function of nucleolin, a multifunctional protein involved in several cellular processes. This review aims at integrating the established hallmarks of cancer with the plasticity of cancer cells as an emerging hallmark; responsible for tumor heterogeneity; therapy resistance and relapse. The discussion will contextualize the involvement of nucleolin in the establishment of cancer hallmarks and its application as a marker protein for targeted anticancer therapies.MDPI2021-01-13info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/105324http://hdl.handle.net/10316/105324https://doi.org/10.3390/ph14010060eng1424-8247Carvalho, Laura SofiaGonçalves, NélioFonseca, Nuno AndréMoreira, João Nunoinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-02-17T09:18:10Zoai:estudogeral.uc.pt:10316/105324Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:21:55.118256Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
title |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
spellingShingle |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis Carvalho, Laura Sofia tumor heterogeneity drug resistance cancer stem cells nucleolin targeted therapies epithelial-to-mesenchymal transition |
title_short |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
title_full |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
title_fullStr |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
title_full_unstemmed |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
title_sort |
Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis |
author |
Carvalho, Laura Sofia |
author_facet |
Carvalho, Laura Sofia Gonçalves, Nélio Fonseca, Nuno André Moreira, João Nuno |
author_role |
author |
author2 |
Gonçalves, Nélio Fonseca, Nuno André Moreira, João Nuno |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Carvalho, Laura Sofia Gonçalves, Nélio Fonseca, Nuno André Moreira, João Nuno |
dc.subject.por.fl_str_mv |
tumor heterogeneity drug resistance cancer stem cells nucleolin targeted therapies epithelial-to-mesenchymal transition |
topic |
tumor heterogeneity drug resistance cancer stem cells nucleolin targeted therapies epithelial-to-mesenchymal transition |
description |
Cancer, one of the most mortal diseases worldwide, is characterized by the gain of specific features and cellular heterogeneity. Clonal evolution is an established theory to explain heterogeneity, but the discovery of cancer stem cells expanded the concept to include the hierarchical growth and plasticity of cancer cells. The activation of epithelial-to-mesenchymal transition and its molecular players are widely correlated with the presence of cancer stem cells in tumors. Moreover, the acquisition of certain oncological features may be partially attributed to alterations in the levels, location or function of nucleolin, a multifunctional protein involved in several cellular processes. This review aims at integrating the established hallmarks of cancer with the plasticity of cancer cells as an emerging hallmark; responsible for tumor heterogeneity; therapy resistance and relapse. The discussion will contextualize the involvement of nucleolin in the establishment of cancer hallmarks and its application as a marker protein for targeted anticancer therapies. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-13 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/105324 http://hdl.handle.net/10316/105324 https://doi.org/10.3390/ph14010060 |
url |
http://hdl.handle.net/10316/105324 https://doi.org/10.3390/ph14010060 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1424-8247 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134109517217792 |